BioCentury | Jul 26, 2017
Emerging Company Profile

Breaching the gates

...to deliver molecules across the BBB, such as 2-BBB Medicines B.V. , Angiochem Inc. , biOasis Technologies Inc....
...junctions Companies and Institutions Mentioned 2BBB Medicines B.V., Leiden, the Netherlands Angiochem Inc., Montreal, Quebec biOasis Technologies Inc....
BioCentury | Sep 26, 2016
Company News

biOasis, Vaccinex deal

...commercialization rights to use biOasis’ Transcend delivery technology with Vaccinex’s anti- semaphorin 4D (SEMA4D) antibodies. biOasis...
...across the blood-brain barrier. Vaccinex directed questions to biOasis, which did not respond to inquiries. biOasis Technologies Inc....
BioCentury | May 2, 2016
Company News

biOasis, Astellas deal

...biOasis and Astellas’ Astellas Research Institute of America LLC unit partnered to develop biOasis’ Transcend technology...
...therapeutics across the blood-brain barrier to brain tissue. The companies declined to disclose additional details. biOasis Technologies Inc....
BioCentury | Sep 7, 2015
Company News

Brigham and Women’s Hospital, biOasis deal

...compounds to treat brain cancers, including glioblastoma tumors. The initial focus will be on advancing biOasis’...
...partners did not respond in time for publication. Brigham and Women’s Hospital , Boston, Mass. biOasis Technologies Inc....
BioCentury | Jul 20, 2015
Company News

biOasis, National Research Council Canada, Universite de Sherbrooke deal

...in-kind donations from the National Research Council. The partners will use in vivo imaging and biOasis’...
...soluble p97 melanotransferrin (sMTf) carrier protein that transports therapeutics across the BBB, to validate candidates. biOasis Technologies Inc....
BioCentury | Sep 1, 2014
Financial News

biOasis proposes private placement of units

biOasis Technologies Inc. (TSX-V:BTI; OTCQX:BIOAF), Vancouver, B.C. Business: Neurology, Diagnostic Date announced: 2014-08-08 Type: Private placement of units To be raised: Up to C$1.5 million ($1.4 million) Units: 1.6 million Price: C$0.95 (unit) Shares outstanding...
BioCentury | Jun 30, 2014
Company News

biOasis management update

...Judi Dalling as CFO and corporate secretary; she succeeds David Clark, who resigned biOasis Technologies Inc. (TSX-V:BTI; OTCQX:BIOAF...
BioCentury | Mar 24, 2014
Company News

biOasis, AstraZeneca deal

...with AstraZeneca's MedImmune LLC biologics unit to evaluate MedImmune's preclinical compounds with next-generation versions of biOasis'...
...version of the Transcend technology in transporting to the brain "compounds of interest" to MedImmune. biOasis...
...positive initial deal led it to undertake this second project (see BioCentury, Nov. 19, 2012). biOasis Technologies Inc....
BioCentury | Feb 18, 2013
Clinical News

biOasis preclinical data

...p<0.0001 for both). BT2111 is trastuzumab conjugated to biOasis' Transcend p97 carrier protein. Next quarter, biOasis...
...Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), markets Herceptin in the U.S., while Roche markets it elsewhere. biOasis Technologies Inc....
BioCentury | Dec 24, 2012
Product Development

Shire homes in

...treat the lysosomal storage disorder metachromatic leukodystrophy. Also, Shire last year said it would evaluate biOasis Technologies Inc....
...Companies and Institutions Mentioned Angiochem Inc. , Montreal, Quebec Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. biOasis Technologies Inc....
Items per page:
1 - 10 of 26
BioCentury | Jul 26, 2017
Emerging Company Profile

Breaching the gates

...to deliver molecules across the BBB, such as 2-BBB Medicines B.V. , Angiochem Inc. , biOasis Technologies Inc....
...junctions Companies and Institutions Mentioned 2BBB Medicines B.V., Leiden, the Netherlands Angiochem Inc., Montreal, Quebec biOasis Technologies Inc....
BioCentury | Sep 26, 2016
Company News

biOasis, Vaccinex deal

...commercialization rights to use biOasis’ Transcend delivery technology with Vaccinex’s anti- semaphorin 4D (SEMA4D) antibodies. biOasis...
...across the blood-brain barrier. Vaccinex directed questions to biOasis, which did not respond to inquiries. biOasis Technologies Inc....
BioCentury | May 2, 2016
Company News

biOasis, Astellas deal

...biOasis and Astellas’ Astellas Research Institute of America LLC unit partnered to develop biOasis’ Transcend technology...
...therapeutics across the blood-brain barrier to brain tissue. The companies declined to disclose additional details. biOasis Technologies Inc....
BioCentury | Sep 7, 2015
Company News

Brigham and Women’s Hospital, biOasis deal

...compounds to treat brain cancers, including glioblastoma tumors. The initial focus will be on advancing biOasis’...
...partners did not respond in time for publication. Brigham and Women’s Hospital , Boston, Mass. biOasis Technologies Inc....
BioCentury | Jul 20, 2015
Company News

biOasis, National Research Council Canada, Universite de Sherbrooke deal

...in-kind donations from the National Research Council. The partners will use in vivo imaging and biOasis’...
...soluble p97 melanotransferrin (sMTf) carrier protein that transports therapeutics across the BBB, to validate candidates. biOasis Technologies Inc....
BioCentury | Sep 1, 2014
Financial News

biOasis proposes private placement of units

biOasis Technologies Inc. (TSX-V:BTI; OTCQX:BIOAF), Vancouver, B.C. Business: Neurology, Diagnostic Date announced: 2014-08-08 Type: Private placement of units To be raised: Up to C$1.5 million ($1.4 million) Units: 1.6 million Price: C$0.95 (unit) Shares outstanding...
BioCentury | Jun 30, 2014
Company News

biOasis management update

...Judi Dalling as CFO and corporate secretary; she succeeds David Clark, who resigned biOasis Technologies Inc. (TSX-V:BTI; OTCQX:BIOAF...
BioCentury | Mar 24, 2014
Company News

biOasis, AstraZeneca deal

...with AstraZeneca's MedImmune LLC biologics unit to evaluate MedImmune's preclinical compounds with next-generation versions of biOasis'...
...version of the Transcend technology in transporting to the brain "compounds of interest" to MedImmune. biOasis...
...positive initial deal led it to undertake this second project (see BioCentury, Nov. 19, 2012). biOasis Technologies Inc....
BioCentury | Feb 18, 2013
Clinical News

biOasis preclinical data

...p<0.0001 for both). BT2111 is trastuzumab conjugated to biOasis' Transcend p97 carrier protein. Next quarter, biOasis...
...Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), markets Herceptin in the U.S., while Roche markets it elsewhere. biOasis Technologies Inc....
BioCentury | Dec 24, 2012
Product Development

Shire homes in

...treat the lysosomal storage disorder metachromatic leukodystrophy. Also, Shire last year said it would evaluate biOasis Technologies Inc....
...Companies and Institutions Mentioned Angiochem Inc. , Montreal, Quebec Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. biOasis Technologies Inc....
Items per page:
1 - 10 of 26